Effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with non‐valvular atrial fibrillation: A nationwide, population‐based study in Korea

• Published in: Journal of arrhythmia 2021-10, Vol.37 (5), p.1240-1249
• Main Authors: Han, Seongwook, Han, Sola, Suh, Hae Sun, Bang, Oh Young, On, Young Keun, Lee, Myung‐Yong, Jang, Sung‐Won, Won, Mi‐Mi, Park, Yoo‐Jung, Lee, Ji‐Min, Kang, Seongsik, Kim, Young‐Hoon
• Format: Article
• Language: English
• Subjects: Age; Anticoagulants; Apixaban; Atrial fibrillation; Cardiac arrhythmia; Care and treatment; Codes; Comparative analysis; Demographics; Disease; Embolisms; Health insurance; Hospitalization; Insurance coverage; intracranial hemorrhage; Magnetic resonance imaging; Neurosurgery; Original; Population; Population-based studies; Rivaroxaban; Sensitivity analysis; Stroke; Stroke (Disease); thromboembolism
• ISSN: 1880-4276; 1883-2148
• DOI: 10.1002/joa3.12607

Background To compare the risk of stroke/systemic embolism (S/SE) and major bleeding (MB) between non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF), this retrospective study was conducted using the Korean Health Insurance Review & Assessment Service (HIRA) claims database. Methods Patients with AF who initiated NOACs (apixaban, dabigatran, and rivaroxaban) from July 1, 2015 to November 30, 2016 were included. We applied inverse probability of treatment weighting (IPTW) method using propensity score to make weighted populations having similar characteristics between groups. Hazard ratio (HR) of S/SE and MB were estimated by Cox proportional hazard model. Results Of the 39 783 patients with AF, 10 564; 11 418; and 17 801 used apixaban, dabigatran, and rivaroxaban, respectively. The mean CHA2DS2‐VASc and HAS‐BLED scores were 4.59 ~ 4.69 and 3.58 ~ 3.62, respectively, among all patients after applying IPTW. For S/SE, there were no significant differences between NOACs (HR [95% confidence interval (CI)]): apixaban vs dabigatran (0.99 [0.87‐1.13]), apixaban vs rivaroxaban (0.95 [0.84‐1.07]), and dabigatran vs rivaroxaban (0.96 [0.85‐1.08]). For MB (HR [95% CI]), both apixaban (0.77 [0.68‐0.86]) and dabigatran (0.88 [0.79‐0.98]) had a significantly lower risk compared with rivaroxaban. Apixaban also had a significantly lower risk of MB compared with dabigatran (0.87 [0.76‐0.99]). Conclusions In real‐world practice among Korean AF patients with relatively high risk of stroke and bleeding, there were no significant differences in the risk of S/SE between all NOAC comparisons. Apixaban was associated with lower risk of MB than dabigatran and rivaroxaban. In real‐world practice among Koreans with AF, there were no significant differences in the risk of S/SE between all NOAC comparisons. Apixaban was associated with lower risk of MB than dabigatran and rivaroxaban.